Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Hypothesis: Schizotypal personality disorder patients will show cognitive improvements in 1)
working memory 2) learning and memory 3) sustained attention 4) enhanced performance on the
AX-CPT, N-back and Eriksen during pergolide treatment. There will be a significant diagnosis
by drug administration of 0.3 mg of oral pergolide interaction for performance on the
cognitive tasks, with the schizotypal personality disorder group demonstrating significantly
improved peformance compared to the other personality disorder group after pergolide compared
with placebo.
Design: Randomized, double-blind, crossover study of pergolide vs. placebo. Half of subjects
receive pergolide for eight weeks; half of subjects receive placebo for four weeks followed
by pergolide for four weeks.